What's Going On With Bio-Path Stock?
What's Going On With Bio-Path Stock?
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML).
Bio-Path Holdings，Inc. (納斯達克：BPTH)股票週一上漲，因公司宣佈公佈前途根諾（BP1001）聯用地塞米松和維諾茲拉替治療急性髓樣白血病(AML)的2期臨床研究的中間結果。
The Details:
細節：
The company presented data on Saturday which showed prexigebersen to be well-tolerated and has demonstrated efficacy results in two reporting cohorts including newly diagnosed AML patients and refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
公司週六公佈的數據顯示，前途根諾對新診斷的AML患者和難治/復發AML患者產生了良好的療效結果，兩個報告群體的療效結果均超過了一線治療的預期。
Related News: What's Going On With Snowflake Stock?
相關資訊：Snowflake的股票發生了什麼？
"We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients," said Peter Nielsen, CEO of Bio-Path.
“我們很榮幸能夠有機會在ASCO上發表口頭報告，這不僅凸顯了我們數據的質量，也突顯了這些最脆弱癌症患者持續存在的不滿足需求。” Bio-Path的CEO Peter Nielsen說。
"We continue to advance this important study confident that prexigebersen can make a difference in the lives of these patients for whom there are limited treatment options."
“我們將繼續推進這一重要研究，有信心前途根諾可以爲這些有限治療選擇的患者帶來改變。”
Bio-Path shares are moving on heavy trading volume on Monday following the announcement. According to data from Benzinga Pro, more than 34.375 million shares have already been traded in the session, compared to the stock's float of only 1.655 million shares.
週一，Bio-Path的股票交易量大幅增加，並隨着公告發布而上漲。根據Benzinga Pro的數據，該股票的成交量已超過3437.5萬股，而其流通股僅爲165.5萬股。
Is BPTH A Good Stock To Buy?
BPTH股票值得買嗎？
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Bio-Path's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
投資者在決定股票是否值得買入時，可以做出一些決策。除了估值指標和價格走勢（您可以在Benzinga的行情頁面中找到，比如Bio-Path的頁面），還有像公司是否支付股息或每個季度購買其股票的大部分股份的因素。
These are known as capital allocation programs. Bio-Path does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
這些被稱爲資本配置計劃。Bio-Path不支付股息，但顯然有幾種方式可以爲股東創造價值。歡迎搜索Benzinga的分紅日曆，查找下一個要支付股息的公司，並確定持有公司股份可以獲得什麼樣的收益率。
For example, if you're looking to earn an annualized return of 13.76%, you'll need to buy a share of Neuberger Berman by June 17, 2024. Once done, you can expect to receive a nominal payout of $0.09 on June 28, 2024.
例如，如果您想獲得13.76%的年化回報率，您將需要在2024年6月17日之前購買紐伯格伯曼（Neuberger Berman）的一股股票。購買完成後，您可以期待在2024年6月28日收到名義支付0.09美元的分紅。
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Bio-Path Hldgs will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
回購計劃顯然是不同的，且高度可變的。公司可以批准回購計劃，並根據其認爲適當的時間購買股票。查看Bio-Path Hldgs的最新消息通常會提示公司是否最近批准了回購計劃。回購計劃通常用作股價支撐，作爲需求的後備。
BPTH Price Action: According to Benzinga Pro, Bio-Path shares are up 80% at $3.71 at the time of publication Monday.
BPTH股票價格動態：根據Benzinga Pro的數據，Bio-Path的股票價格在週一出版時上漲80%，爲3.71美元。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。